Free Trial

Silexion Therapeutics Q2 2024 Earnings Report

Silexion Therapeutics logo
$0.99 -0.05 (-4.62%)
As of 04:00 PM Eastern

Silexion Therapeutics EPS Results

Actual EPS
-$52.83
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Silexion Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Silexion Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

Silexion Therapeutics Earnings Headlines

Silexion Therapeutics announces expanded development plan for SIL204
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Silexion announces completion of expanded development plan for SIL204
Silexion Therapeutics price target lowered to $5 from $9 at Maxim
See More Silexion Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Silexion Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silexion Therapeutics and other key companies, straight to your email.

About Silexion Therapeutics

Silexion Therapeutics (NASDAQ:SLXN) LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

View Silexion Therapeutics Profile

More Earnings Resources from MarketBeat